Brain tumors are the leading cause of cancer-related deaths in children and require a collaborative, transdisciplinary approach to increase survival rates.
The following brain tumor experts are available to offer information on pediatric brain cancer. To schedule an interview, email media@stjude.org.
Brain Tumor Experts
-
Suzanne J. Baker, PhD
Baker
Suzanne Baker, PhD, St. Jude Department of Developmental Neurobiology, serves as Director of the Division of Brain Tumor Research, and Associate Director of Basic Research, within the St. Jude Comprehensive Cancer Center. Baker’s research seeks to understand normal and cancer cell growth in the brain, specifically focusing on childhood high-grade gliomas and diffuse intrinsic pontine gliomas.
-
Amar Gajjar, MD
Gajjar
Amar Gajjar, MD, St. Jude Department of Pediatric Medicine chair, develops innovative clinical protocols for treating childhood brain tumors, working with investigators in basic science laboratories to translate the latest scientific findings into actionable therapies for patients.
-
Thomas E. Merchant, DO, PhD
Merchant
Thomas Merchant, DO, PhD, St. Jude Department of Radiation Oncology chair, focuses on clinical applications for advanced radiation therapy for pediatric brain tumors. He also oversees the hospital’s best practices using proton beam therapy.
-
Paul A. Northcott, PhD
Northcott
Paul Northcott, PhD, St. Jude Department of Developmental Neurobiology, focuses on solving the molecular and cellular origins of medulloblastoma. His laboratory aims to comprehensively understand the genetic, epigenetic and transcriptional landscapes underlying medulloblastoma.
-
Giles W. Robinson, MD
Robinson
Giles Robinson, MD, St. Jude Neuro-Oncology Division director in the Department of Oncology, seeks to improve survival rates and reduce treatment-related side effects for children with brain and central nervous system tumors. As a leader in clinical research, Robinson developed, launched and currently operates the first clinical trial to tailor therapy according to the tumor’s molecular makeup for children with brain cancer.
